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Background: To validate a gradient-based segmentation method for gross tumor volume(GTV) delineation on
8F-fluorothymidine (FLT)positron emission tomography (PET)/ computer tomography (CT) in esophageal squamous
cell cancer through pathologic specimen, in comparison with standardized uptake values (SUV) threshold-based
methods and CT. The corresponding impact of this GTV delineation method on treatment planning was evaluated.
Methods and materials: Ten patients with esophageal squamous cell cancer were enrolled. Before radical surgery,
all patients underwent FLT-PET/CT. GTVs were delineated by using four methods. GTVGRAD, GTV1.4 and GTV30%max
were segmented on FLT PET using a gradient-based method, a fixed threshold of 1.4 SUV and 30% of SUVmax,
respectively. GTVCT was based on CT data alone. The maximum longitudinal tumor length of each segmented GTV
was compared with the measured tumor length of the pathologic gross tumor length (LPath). GTVGRAD, GTV1.4 and
GTV30%max were compared with GTVCT by overlap index. Two radiotherapy plannings (planGRAD) and (planCT) were
designed for each patient based on GTVGRAD and GTVCT. The dose-volume parameters for target volume and normal
tissues, CI and HI of planGRAD and planCT were compared.
Results: The mean ± standard deviation of LPath was 6.47 ± 2.70 cm. The mean ± standard deviation of LGRAD,L1.4, L30%max
and LCT were 6.22 ± 2.61, 6.23 ± 2.80, 5.95 ± 2.50,7.17 ± 2.28 cm, respectively. The Pearson correlation coefficients between
LPath and each segmentation method were 0.989, 0.920, 0.920 and 0.862, respectively. The overlap indices of GTVGRAD,
GTV1.4, GTV30%max when compared with GTVCT were 0.75 ± 0.12, 0.71 ± 0.12, 0.57 ± 0.10, respectively. The V5, V10, V20, V30
and mean dose of total-lung,V30 and mean dose of heart of planGRAD were significantly lower than planCT.
Conclusions: The gradient-based method provided the closest estimation of target length. The radiotherapy plannings
based on the gradient-based segmentation method reduced the irradiated volume of lung, heart in comparison to CT.
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Radiotherapy (RT) is one of the most important treatment
modalities for esophageal cancer. CT has been the stand-
ard of GTV delineationn in esophageal cancer, however,
there is growing interest in using PET-guided GTV delin-
eation [1] to take advantage of increased contrast between
tumor and surrounding normal tissue.* Correspondence: 119487955@qq.com
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unless otherwise stated.18F-fluorodeoxyglucose (FDG) is the most frequently used
radiopharmaceutical for oncologic PET scanning. However,
FDG-PET has limitations in specificity. False-positive results
can be caused by inflammation, including peritumoural in-
flammatory reactions [2]. Studies have shown that FLT is a
good imaging tracer for cell proliferation [3-6] and tumor
volume change [7]. However, little data is available on the
clinical use of FLT-PET in various carcinomas [8-10], in-
cluding esophageal cancer.
A number of methods have been used for GTV delinea-
tion in PET including manual contouring [11,12] and semi-
automatic threshold-based segmentation [13,14]. However,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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limitations gradient-based segmentation method has been
developed to identify the tumor based on changes in count
levels at the tumor border. This method has been validated
using phantoms [15,16] and through comparison to patho-
logic specimens for head and neck carcinoma [15] and non-
small-cell lung cancer (NSCLC) [17]. However, data for
GTV delineation in esophageal cancer using gradient-based
segmentation is lacking and in particular using FLT-PET.
Our goal in this current study was to validate a gradient-
based segmentation method for GTV delineation in esopha-
geal cancer through pathologic specimens in comparison
with SUV thresholds and CT. The impact of using the
gradient-based delineated GTV in comparison to the CT
delineated GTV was evaluated using dose volume parame-
ters of the lung, heart, and spinal cord.
Methods and materials
Patients selection
Ten patients (mean age 60 years, range 52-75) with histolog-
ically proven esophageal squamous cell carcinoma were pro-
spectively enrolled in this study between September 2008
and January 2009. Four patients had middle thoracic
esophageal cancer, and six had lower thoracic disease. None
of the patients had previously been treated with preoperative
chemotherapy or RT. First, all patients underwent routine
pretreatment evaluation, including physical examination,
complete blood count, biochemistry surveys of liver and kid-
ney function, chest radiographs, electrocardiograms, barium
esophagograms, esophagogastroscopy with tumor biopsy,
ultrasound evaluation of the neck and abdomen, and pul-
monary function testing. Informed consent was obtained
from all patients.
Image acquisition
FLT-PET/CT image acquisitions were performed within 4
days prior to surgical tumor resection with a dedicated
PET/CT scanner (Discovery LS, GE Healthcare). The pa-
tients fasted for at least 6 hours and rested for 15 minutes
before the injection of 300–400 MBq of FLT. Images were
obtained 60 min after injection. The scans were performed
for 5 min/ bed position from head to femur, each covering
14.5 cm, at an axial sampling thickness of 4.25 mm/slice.
Both PET and CT acquisition were performed in free respir-
ation. Data were reconstructed using an iterative reconstruc-
tion technique and attenuation correction derived from CT
data. The CT,PET and fused PET/CT images were transmit-
ted to MIM Maestro (MIM Software Inc, Cleveland, OH)
for GTV delineation.
Delineation of GTV
For each patient, four different GTVs were generated
(Figure 1). The PET/CT images were reviewed by one
experienced nuclear medicine physician and a radiationoncologist, GTVGRAD, GTV1.4 and GTV30%max were
automatically segmented on PET images using the
gradient-based method, fixed threshold values at 1.4
SUV and 30% of SUVmax. The longitudinal gross tumor
length of GTVGRAD, GTV1.4 and GTV30%max, were re-
corded as LGRAD, L1.4 and L30%max, respectively. One ex-
perienced radiologist and one radiation oncologist, both
unaware of the results from PET or surgery, segmented
the CT images (GTVCT), using esophageal wall thickness
of 5 mm or more and esophageal wall diameter without
gas more than 10mm as the criteria of primary tumor.
The longitudinal gross tumor length of CT was mea-
sured and recorded as LCT. Figure 1 shows case that
overview of the tumor delineated by different methods.
The 1.4 SUV threshold was chosen based on a previous
study [7] and the 30% of SUVmax was based on clinical
experience. The method for gradient-based segmenta-
tion has been previously described. “It calculates spatial
derivatives along the tumor radii and then defines the
tumor edge on the basis of derivative levels and continu-
ity of the tumor edge. The software relies on an
operator- defined starting point near the center of the
lesion. As the operator drags out from the center of the
lesion, 6 axes extend out, providing visual feedback for
the starting point of gradient segmentation. Spatial gra-
dients are calculated along each axis interactively, and
the length of an axis is restricted when a large spatial
gradient is detected along that axis. The 6 axes define an
ellipsoid that is then used as an initial bounding region
for gradient detection [16]”. The fixed SUV threshold
methods involved placing a user-defined sphere over the
tumor and applying the threshold inside of the sphere to
segment the tumor.
Processing of the surgical specimen
All patients underwent transthoracic esophagectomy with
conventional two-or three-field lymphadenectomy. The
specimens were flattened within 30 min after surgical resec-
tion, stretched to same length as measured in-situ, pinned
on a plastic foam-board, then soaked and fixed with 10%
formaldehyde. The specimens were cut into 5mm-wide
strips of tissue following longest dimension of the tumor
(including upper and lower margin)to create the patho-
logical sections [7]. LPath is defined as the pathological
gross tumor length as measured under a low magnifica-
tion microscope.
GTV data analysis
The longitudinal gross tumor length and volumes of
GTVs derived from different delineation methods were
compared.
The mean and standard deviation of longitudinal gross
tumor length for each of the segmentation method was cal-
culated. LGRAD, L1.4 and L30%max were compared with LPath
Figure 1 Overview of the tumor delineation for one patient with middle thoracic esophageal cancer. (A) Gross tumor lengths delineated
on CT images by different methods. (B) Gross tumor lengths delineated on FLT PET/CT images by different methods. Volumes are displayed in
transaxial, sagittal and coronal planes. Purple, orange, blue and Red contours illustrate different parameters (e.g. GRAD, 1.4 SUV threshold, 30% of
SUVmax and CT).
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fined as the “gold standard,” but because the correction co-
efficient does not allow preference between GTVPET and
GTVCT, an overlap index (OI) was also calculated for each
set of contours according to the expression:
OI ¼ GTVPET ∩GTVCT
GTVCT
The OI reflects the inclusion of GTVPET within
GTVCT [18].
Treatment planning design and evaluation
Both PET and CT data for all patients were transmitted to
a Pinnacle3 treatment planning station (Philips, 8.0 m).
The clinical target volume (CTV) was created using a
3 cm margin in the craniocaudal direction (following
the course of the esophagus) and a 1 cm margin in the
lateral and anteroposterior directions beyond GTVGRAD
and GTVCT. The CTV was then expanded in all direc-
tions by 0.5 cm to create the planning target volume
(PTV): PTVGRAD and PTVCT. Two treatment plannings,
planGRAD and planCT were designed based on PTVGRAD
and PTVCT, respectively. The radiation dose was pre-
scribed as 60Gy in 30 fractions using a five-beam con-
formal radiotherapy treatment. The treatment plannings
of a 67-years-old female patient with middle thoracic
esophageal cancer were showed in Figure 2. The plans
were designed to meet the following treatment planning
goals: >95% of the PTV covered by the prescriptionisodose line, V20 of total lung < 30%, V40 of heart < 30%
and Dmax of spinal cord < 45 Gy.It was required that there
was no cold spot in the PTV and no hot spot in esopha-
geal wall. Cumulative DVHs were generated for evaluation
and comparison of planGRAD and planCT. For PTV, the
values of HI (heterogeneity index) and CI (conformal
index) were compared. The mean lung dose (MLD), V5
(volume included by 5Gy isodose curve), V10, V20, V30 and
mean lung dose of total lung, V30 (volume included by
30Gy isodose curve), V40, mean heart dose (MHD) of heart
and maximum dose of spinal cord (Dmax) were recorded.
Statistical analysis
The Statistical Package for Social Sciences, version 13.0
(SPSS, Chicago, IL) was used for statistical analysis. The
two-tailed paired Student’s t-test was applied to assess
the differences between groups and Pearson’s correlation
were performed to assess the relationship between
groups. A p value of <0.05 was considered statistically
significant. HI = (D2-D98)/prescription dose * 100% [19];
and CI = Vt,ref/Vt * Vt,ref/Vref [20]. [Note: Vt = target
volume, Vt,ref = target volume wrapped by reference iso-
dose, Vref = all volume wrapped by reference isodose].
CI values range beetween 0 and 1 with a value closer to
1 represents a better conformity.
Results
The mean of LPath was (6.47 ± 2.7) cm (range, 3.44-
11.00 cm). Of the 10 primary cancers, 4 were >5 cm and
6 were <5 cm. The mean length obtained using each
Figure 2 Treatment planning simulated with FLTPET/CT for 67-years-old female patient with middle thoracic esophageal cancer.
(A) FLT PET/CT-based five-beam conformal radiation therapy (B) CT-based five-beam conformal radiation therapy.
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relation coefficients of LGRAD, L1.4, L30%max, LCT with LPath
were 0.989 (P < 0.05), 0.920 (P < 0.05), 0.920 (P < 0.05),
0.862 (P < 0.05), respetively. In comparison to the PET de-
termined GTV, LCT led to a large over estimation of LPath.
LGRAD seemed to more greatly approximate to LPath.
The mean volume of GTVCT was (38.37 ± 30.04) cm
3
(range: 14.41-105.11 cm3),the mean volume obtained using
each segmentation method was depicted in Figure 4. TheFigure 3 The mean Length obtained using different methods. Error baGTVs generated from FLT PET/CT were significantly
smaller than GTVCT (P < 0.05). The mean OI of GTVGRAD,
GTV1.4 and GTV30%max with GTVCT were 0.75 ± 0.12,
0.71 ± 0.12 and 0.50 ± 0.10, the OI of GTVGRAD with
GTVCT was higher than GTV1.4, but the difference be-
tween GTVGRAD and GTV1.4 was not significant.
Next, two RT simulation plannings using gradient-based
segmentation method on FLT PET/CT and CT delineating
target volumes in the Philips Pinnacle3 treatment planningrs indicate standard deviation.
Figure 4 The mean volume obtained using different methods. Error bars indicate standard deviation.
Table 2 Comparison of FLT and CT-based overall values
of measured dose–volume histogram-based evaluation
factors for esophageal cancer patients
Mean ± SD planGRAD planCT t P
Total-lung
V5 (%) 47.9 ± 15.30 56.1 ± 13.80 −6.31 0.000
V10 (%) 33.8 ± 8.90 40.1 ± 9.10 −6.78 0.000
V20 (%) 18.2 ± 10.00 23.8 ± 9.70 −4.36 0.003
V30 (%) 5.49 ± 4.40 8.9 ± 4.70 −3.17 0.016
MLD (Gy) 9.82. ± 319.50 10.96 ± 3.02 −4.70 0.002
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the criteria that >95% of the PTV were covered by the
prescription isodose line and the global hotspot was <10%.
In Tables 1 and 2 the evaluation factors of PTVGRAD and
PTVCT were listed. The difference in CI, HI, V40 of heart
and Dmax of spinal cord between planGRAD and planCT
were not significantly different. However, the V5,V10,V20,
V30 and mean dose of total-lung, V30 and mean dose of
heart of planGRAD were significantly lower than planCT.
Discussion
The developments of functional imaging techniques
such as PET/CT have brought biologically-guided IMRT
to the forefront of radiotherapy. Biologically-guided
intensity-modulated radiation therapy (IMRT) has
shown the advantages over traditional anatomically-
based IMRT, in terms of GTV contouring, treatment
planning optimization, and prognosis determination
[21]. PET has been shown to supplement the informa-
tion lacking in anatomical images and improves the ac-
curacy of target volume segmentation [22]. FDG-PET
image has shown the capability to accurately determine
the length of esophageal tumors and GTV delineation
more accurate, and improving treatment planning com-
pared to anatomical imaging [23]. While FDG-PET has
long been the most used tracer for biologic tumorTable 1 Comparison of CI and HI of two group plannings
Parameter planGRAD planCT t P
CI 0.75 ± 0.06 0.74 ± 0.06 0.94 0.38
HI 1.13 ± 0.02 1.14 ± 0.03 −1.16 0.28imaging, in recent years, FLT has garnered attention
due to its ability to characterize tumor proliferation.
In our study, we evaluated the accuracy of a gradient-
based segmentation method for GTV delineation with FLT-
PET using pathologically determined EC length as the gold
standard. SUV threshold methods and CT visual delinea-
tion were used for comparison. Additionally we explored
the feasibility of the use of FLT-PET with gradient-based
segmentation for treatment planning. While all segmenta-
tion methods were found to correlate well with LPath, the
gradient-based results were the most consistent with the
pathologic results. Werner-Wasik M et al [16] demon-
strated similar results for their gradient-based segmentation
method when they found their method was more accurateHeart
V30 (%) 37.6 ± 19.30 44.1 ± 20.80 −5.97 0.000
V40 (%) 20.8 ± 13.50 22.8 ± 14.10 −1.19 0.272
MHD (Gy) 22.63 ± 10.25 25.37 ± 10.71 −5.92 0.000
Dmax of spinal cord (Gy) 44.26 ± 1.36 44.69 ± 0.29 −0.94 0.380
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when compared to a volumetric pathology gold standard.
Common methods of GTV segmentation for PET/CT
images included visual judgement and SUV thresholds.
Visual judgement relies solely on the visual discrimination
of tumor boundaries, which is subjective and leads to inter
observer bias. In addition, differences in window and level
contrast settings contribute to variability [22]. Threshold
methods often use a fixed SUV or a certain percentage of
the maximum SUV as the threshold [23]. These methods
are limited with regard to variations in tumor size which
affect image count levels due to partial volume effects,
variable tumor to background activity, and heterogeneous
tracer uptake in the tumor. Gradient-based methods use
the maximum spatial gradient to detect boundaries
between lesions and normal tissue [24], which is not af-
fected by different imaging equipments, reconstruction
algorithms and sphere diameter effects [16]. It overcomes
the limitations of visual judgement and SUV threshold
methods.
The gradient and 1.4 SUV threshold methods had
tumor lengths that were the most closely related to patho-
logically determined tumor lengths acquisition, and recon-
struction variables that can significantly affect SUV
measurements in typical less controlled clinical situations
[1]. These factors would also impact the size of lesions de-
tected with the absolute 1.4 SUV threshold, but do not
affect the gradient –based measurement of lesion size
which is based on detecting the maximum change in SUV
levels regardless of their absolute value.
The CT segmentation result was found to overestimate
the tumor length compared to pathology. This coincides
with the results of Konski et al. [25], in which 25
esophageal cancer patients were scanned using CT and
PET/CT. In their study the PET/CT scans showed a
mean tumor length of 5.4 cm compared to 6.77 cm from
CT, representing a statistically significant difference.
The CT-based contours also were found to be larger
in size than the gradient-based contours, which may be
due to the fact that the entirety of the esophageal wall is
typically included in the CT-defined GTV, regardless of
which part of the wall the tumor is in. Since the target
volume shown in FLT-PET images represents FLT up-
take activity, it could include the entire esophageal wall
or just part of the wall. In addition, inflammation will
show a thickened esophageal wall in CT images, whereas
this may not affect the uptake activity shown in FLT
PET images.
3DCRT plans using PTVGRAD and PTVCT were designed
to compare dosimetric differences between treatment plan-
nings using target volumes delineated with gradient-based
and CT-based methods respectively. As shown, GTVGRAD
was smaller in volume than GTVCT, and the outer borders
caused even greater differences in PTV volume, which hasa direct impact on the dose given to normal tissue. While
conformality and homogeneity of the two groups of PTVs
were similar, planGRAD resulted in significantly lower organ
at risk doses than planCT. To some extent, this would re-
duce the side effects of radiotherapy, thereby improving pa-
tient quality of life and prognosis. However, it has also been
reported in the literature that FLT PET/CT will miss some
small primary tumors [26], so a variety of imaging modal-
ities should be combined with caution in clinical practice.
The major limitation of our study is that the GTV infor-
mation on the specimens was not obtained due to some
technical reasons. The esophagus is an organ composed of
musculature and lumen; the esophageal specimen will
contract and deform after being resected, including the
tumor [27]. Therefore, the volume measured on a speci-
men may not reflect their real values in situ. We measured
the length of the specimen in situ and pinned the speci-
men to a flat board before fixing it with 10% formalde-
hyde, hoping this method would be less influenced by the
deformation of esophageal lumen and thus provide an
approximate estimation. Another limitation of the present
study was the limited number of patients, to evaluate
whether the integration of FLT PET/CT into radiotherapy
of esophageal cancer can actually improve the treatment
outcomes, a larger sample prospective investigation with
data of treatment failures after radiotherapy planning
based on PET/CT is worthy of expectation.Conclusions
Gradient-based segmentation provides a more precise
method for esophageal cancer delineating than SUV thresh-
olds or CT visual delineation using FLT-PET/CT, laying the
foundation for future development in FLT-PET/CT and
BTV-based treatment planning of esophageal cancer. Fur-
ther research needs to be done to validate this work using
larger sample sizes and assessing the clinical impact of treat-
ment plannings designed using gradient-defined biologic
tumor volumes.
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